Canaccord Genuity Maintains Buy on Apogee Therapeutics, Raises Price Target to $130

Canaccord Genuity analyst Edward Nash has maintained a Buy rating on Apogee Therapeutics (NASDAQ: APGE) and raised the price target from $89 to $130. This adjustment reflects an optimistic outlook on the company's performance.